Autoantigens are the substances that cause an autoimmune attack, but it’s not clear which ones are responsible for a person’s diabetes, according to Simi Ahmed, a senior scientist at JDRF (formerly the Juvenile Diabetes Research Foundation) in New York City

A small clinical trial showed an immune system therapy was safe for people with type 1 diabetes, British researchers report.

The immunotherapy also showed signs of helping to keep insulin production steady in people newly diagnosed with the disease, the study authors said. However, because this was a placebo-controlled safety trial, there weren’t enough people included to know for sure how well the treatment works.

The therapy is similar to an allergy shot in the way it works, the researchers explained.

“Type 1 diabetes comes about when the immune system inadvertently and irreparably damages beta cells that make insulin,” said one of the study’s authors, Dr. Mark Peakman. He’s a professor of clinical immunology at King’s College London in England.

Insulin is a naturally occurring hormone that helps usher the sugar from foods into the body’s cells to be used as energy. If the immune system continues to attack the beta cells, which are found in the pancreas, a person with type 1 diabetes will no longer make enough insulin to meet the body’s needs. It’s at this point that they must take insulin injections or use an insulin pump to replace the lost insulin.

Peakman and his colleagues are trying to stop the attacks on the beta cells.

“We have learned that immune attacks like this can be suppressed by immune cells called T-regs (regulatory T cells),” Peakman said.

When people develop type 1 diabetes, it’s likely that they don’t have enough of the right type of T-regs or those T-regs aren’t working very well. So, the investigators developed a type of treatment called peptide immunotherapy using disease-related autoantigens.

Autoantigens are the substances that cause an autoimmune attack, but it’s not clear which ones are responsible for a person’s diabetes, according to Simi Ahmed, a senior scientist at JDRF (formerly the Juvenile Diabetes Research Foundation) in New York City.

Ahmed said the immunotherapy re-educates the immune system, and teaches the cells that they shouldn’t attack the beta cells.

Peakman pointed out that the researchers “used peptide immunotherapy as a way to try and induce more of these cells and/or make them work better. Our results show encouraging signs that this can be achieved. Next steps will be bigger trials to test whether the therapy can halt beta cell damage.”

And, he added, “Scientists think this works by enhancing natural immune networks that control inflammation.”

The study included 27 people with type 1 diabetes who had been diagnosed with the disease within 100 days. The study volunteers were randomly selected to be in one of three groups: 카지노사이트 a placebo group; a group given immunotherapy once every four weeks; and a group that received the immunotherapy injection once every two weeks.

The study team measured levels of a substance called C-peptide, which is created when insulin is produced. Stable or increasing levels of C-peptide indicate that insulin is being made. Declining levels indicate that less insulin is being made.

The volunteers given immunotherapy once every four weeks saw no decline in C-peptide, the findings showed. The group given the treatment once every two weeks saw a decrease in C-peptide at the 12-month mark. Those given a placebo had decreased C-peptide levels at 3, 6, 9 and 12 months.

Peakman said there weren’t enough people in the study to know why there were slight differences in the treatment groups. That’s for a larger study to figure out, he suggested.

But the researchers found that the treatment was quite safe, and there were no side effects “of note,” Peakman added.

The study also looked at insulin use. Over 12 months, insulin use went up by 50 percent in the placebo group. But there was no increase in the treated groups.

And even though all the study volunteers still needed insulin, both diabetes experts said that the need for less insulin would likely improve quality of life and lessen complications.

It’s not yet clear from this trial how often the treatment would need to be given to keep the immune attack at bay.

It’s also not clear if it could benefit people who’ve had type 1 diabetes for a while. Peakman said it probably wouldn’t help them because most of their beta cells would be gone. But Ahmed noted that if someone had detectable C-peptide levels, it’s possible that this treatment or future ones that may contain more than one autoantigen might have an effect.

In December 2016, a study published in Diabetologia found that about one-third of people with type 1 diabetes for at least 10 years still had detectable C-peptide levels. And two-thirds of them showed signs of an ongoing immune system attack.

Findings from the new study were published Aug. 9 in Science Translational Medicine.

Related Posts

Hanan Ashrawi, a senior Palestinian official, said Israel’s settlement plans are a slap in the face of the Palestinians and Kerry
In it, Garzon, a slightly-built 52-year-old with short-cropped gray hair and glasses, appears shaken and at times hesitant. He sits in a simple chair in front of the judge, with four rows of chairs behind him in the small courtroom. Garzon is wearing a dark jacket and trousers with an open-necked shirt. Behind him are two men in dark uniforms, and several other unidentified people are in the room. He also answers questions from a prosecutor. Garzon’s testimony added little new to what is already known about the crash on the evening of July 24 as the high-speed train, carrying 218 people in eight carriages, approached the capital of Spain’s northwestern Galician region. But the video was the public’s first look at the court testimony of the driver who walked away from the accident with a gash in his head. ABC said its footage showed 18 minutes of excerpts from the full 55-minute session, accompanied by what it said was a transcript of the full session. The paper said it obtained a copy of the video that the court took of the session but has not made public. The train had been going as fast as 119 mph (192 kph) shortly before the derailment. The driver activated the brakes “seconds before the crash,” reducing the speed to 95 mph (153 kph), according to the court’s preliminary findings based on black box data recorders. The speed limit on the section of track where the crash happened was 50 mph (80 kph). In his Sunday night testimony, Garzon said he was going far over the speed limit and ought to have started slowing down several miles (kilometers) before he reached the notorious curve. Asked whether he ever hit the brakes, Garzon replied, “The electric one, the pneumatic one … all of them. Listen, when … but it was already inevitable.” His voice shakes, his sentences break down and he appears close to tears as he replies to a question about what was going through his mind when he went through the last tunnel before the curve. “If I knew that I wouldn’t think it because the burden that I am going to carry for the rest of my life is huge,” he said. “And I just don’t know. The only thing I know, your honor, sincerely, is that I don’t know. I’m not so crazy that I wouldn’t put the brakes on.” Garzon said that after the derailment he called central control in Madrid about the accident. “At the speed I was going and the smashup, though I couldn’t see what was behind me. I knew what I was up against and I knew it was inevitable that there was a calamity and so (I called Madrid) to activate the emergency protocol,” he testified. Garzon also explained a photograph on his Facebook page which showed a train speedometer registering 124 mph (200 kph). He said he took the photo “as a laugh or whatever you want to call it” while a colleague was driving a test train on a different track some time ago. His Facebook page was taken down shortly after the crash. It is not known who removed it. The investigating judge is trying to establish whether human error or a technical failure caused the country’s worst rail accident in decades, and Garzon is at the center of the investigation. The judge provisionally charged Garzon on Sunday with multiple counts of negligent homicide. Garzon was not sent to jail or required to post bail because none of the parties involved felt there was a risk of him fleeing or attempting to destroy evidence, according to a court statement. National rail company Renfe said Garzon is an employee with 30 years of experience who became an assistant driver in 2000 and a fully qualified driver in 2003. Garzon went back to court, voluntarily, to offer more testimony on Wednesday. In that second appearance, he said he was talking by phone to the train’s on-board ticket inspector moments before the accident and hung up just before the train left the tracks. But that contradicted what the court said the black boxes showed – that Garzon was on the phone at the time of the derailment. The court said the inspector would testify Friday as a witness. It said the judge has ruled that while the phone call was inappropriate it could not be considered a cause of the accident. Health authorities say 57 people from the crash are still in the hospital, 11 of them in critical condition.
Prosecutors say the suspect confessed to being under the influence of alcohol and drugs when he got into an argument with a woman he did not know in a park

No comments

Leave a Reply

Your email address will not be published. Required fields are marked *